| Literature DB >> 29326785 |
Abbas Ahmadi1, Saleh Bamohabat Chafjiri1, Rajab Ali Sadrkhanlou1.
Abstract
Busulfan is an alkylating agent affects ovarian follicles growth by oxidative stress induction. Satureja khuzestanica has antioxidant effects. The aim of this study was to examine whether S. khuzestanica essential oil (SKEO) exhibits protective effects on busulfan-induced ovarian failure. Eighty-four adult female mice were divided into six groups including dimethyl sulfoxide (control), SKEO 225.00 mg kg-1 (orally), busulfan 3.00 mg kg-1 (orally), busulfan 36.00 mg kg-1 (intraperitoneally), busulfan 3.00 mg kg-1 and SKEO and busulfan 36.00 mg kg-1 and SKEO. After 28 days, the mice were euthanized and oocytes were removed for in vitro fertilization (IVF) rate evaluation. Oocyte quantity and quality, fertilization rate and pre-implantation embryo development were daily examined with a stereo microscope in a period of 120 hr. Serum levels of estradiol and progesterone were also evaluated. Busulfan caused significant decreases in oocyte number and quality, fertilization rate, pre-implantation embryo development and embryo quality. The SKEO significantly decreased the adverse effects of busulfan. The present study indicated that SKEO can protect female fertility potential against busulfan induced damages.Entities:
Keywords: Busulfan; Infertility; Mouse; Ovary; Saturejakhuzestanica
Year: 2017 PMID: 29326785 PMCID: PMC5756246
Source DB: PubMed Journal: Vet Res Forum ISSN: 2008-8140 Impact factor: 1.054
Comparative assessment of oocyte quality and quantity, fertilization and embryo developmental rates in the control and experimental groups. Data are presented as number (%).
|
|
|
|
|
|
|
| |||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
|
| 164 | 161(98.18) | 153(95.04) | 140(91.51) | 100(65.36) | 40(26.15) | 3(1.97) | 12(7.85) | 25(17.65) |
|
| 193 | 193(100.00) | 193(100.00) [ | 193(100.00) | 176(91.20) [ | 17(8.81)[ | 0(0.00) | 6(3.11) | 11(6.22) [ |
|
| 338 | 280(82.85) [ | 230(82.15) [ | 170(73.92) [ | 142(61.74) [ | 88(37.27) [ | 30(13.05) [ | 26(11.31) [ | 32(13.92) [ |
|
| 108 | 80(74.08) [ | 44(55.00) [ | 24(54.55) [ | 4(9.10) [ | 40(90.91) [ | 8(18.19) [ | 20(45.46) [ | 12(27.28) [ |
|
| 150 | 130(86.67) [ | 115(88.47) [ | 111(96.53) [ | 70(60.87) [ | 45(39.14) [ | 25(21.74) [ | 11(9.57) [ | 9(7.83) [ |
|
| 266 | 222(83.46) [ | 176(79.28) [ | 138(78.41) [ | 114(64.78) [ | 62(35.23) [ | 16(9.10) [ | 20(11.37) [ | 26(14.78) [ |
Different superscript letters indicate significant differences as follow:
compared to control group,
compared to 225.00 mg kg-1 SKEO (group 2),
compared to 3.00 mg kg-1 busulfan (group 3),
compared to 36.00 mg kg-1 busulfan (group 4),
compared to 3.00 mg kg-1 busulfan and 225.00 mg kg-1 SKEO (group 6) at p < 0.05.
Fig. 1Representative photomicrographs of in vitro embryo development: A) Shows normal blastocysts in SKEO-treated group (100×); B) Busulfan 3.00 mg kg-1 group (200×); C) Busulfan 36.00 mg kg-1 group: Embryos arrested and type I, II and III of embryo quality (100×); D) Busulfan 3.00 mg kg-1 and SKEO group (100×); E) Busulfan 36.00 mg kg-1 and SKEO group (100×). Blue and black arrows indicate normal and arrested embryos, respectively.
Comparative assessment of serum concentrations of sex steroids in the control and experimental groups (mean ± SEM).
|
|
|
|
|---|---|---|
|
| 41.80 ± 0.31 | 5.30 ± 0.05 |
|
| 64.70 ± 1.43[ | 8.07 ± 0.28 [ |
|
| 21.70 ± 1.58 [ | 2.02 ± 0.26 [ |
|
| 27.80 ± 1.19 [ | 2.07 ± 0.17 [ |
|
| 34.30 ± 1.25 [ | 4.52 ± 0.08 [ |
|
| 35.10 ± 1.05 [ | 4.05 ± 0.09 [ |
Different superscript letters indicate significant differences as follow:
compared to control group,
compared to 225.00 mg kg-1 SKEO (group 2),
compared to 3.00 mg kg-1 busulfan (group 3),
compared to 36.00 mg kg-1 busulfan (group 4),